Turbine
Hungary
- Budapest
- 20/06/2023
- Series A
- $6,004,625
Turbine was founded for a simple reason; to understand complex cancers better than existing experimental tools in order to solve unmet oncology needs.
Through a multidisciplinary team that unites computer science and molecular biology, and the world's most intricate simulation of cell behavior, we identify treatment options for the 70% of cancers that are currently unexplored.
We use our platform, the Simulated Cell™, to uncover novel biological insights across both new and known targets. This allows us to provide a fresh biological context, define responsive patient populations, and design drug combination approaches that diminish resistance.
With a process proven by clinical stage predictions and a proprietary pipeline, we continue our mission of unlocking cancer complexity to deliver next-generation precision therapeutics.
- Industry Biotechnology Research
- Website https://turbine.ai/
- LinkedIn https://www.linkedin.com/company/turbine-inc/
EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)